Oncolytics Biotech Inc (ONCY) Stock Price, Quote & News

Company Profile

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoin...

Industry: Biotechnology

Sector: Healthcare

Phone: 403-670-7377

Fax: 403-283-0858

Website: oncolyticsbiotech.com

Address:

322 11th Avenue SW, Suite 804, Calgary, Canada

ChartGeek Jul. 12 at 12:49 AM

$ONCY on watchlist

0 · Reply

cbachand Jul. 11 at 5:39 PM

$ONCY FDA Commissioner, Dr. Marty Makary, has indicated today that the FDA's new priorites will include delivering "more innovative cures" and addressing unmet public health needs, as he wants to see more treatments for stage 4 cancer, or when the disease has spread from its original site to distant parts of the body, such as in advanced or metastatic cancers.

0 · Reply

JoeZa Jul. 11 at 2:16 PM

$ALT picked up a position $ONCY

1 · Reply

CaseyLe Jul. 11 at 1:13 PM

$ONCY 73 days left

1 · Reply

Arrankar2099 Jul. 11 at 6:33 AM

$ONCY

1 · Reply

De_man Jul. 11 at 12:16 AM

$ONCY ok and just throwing this out there. The kol pr did not overly impress as they just did one in April BUT WHAT IF it is in conjunction with a gcar announcement or some kind of trial updates now that would be nice.

1 · Reply

sam92 Jul. 10 at 4:50 PM

$ONCY Latest Report 07/09/2025 LSEG maintains a current price target of $3.43 for ONCY

0 · Reply

Lovelife68 Jul. 10 at 3:20 PM

$ONCY hi how much cash does oncy have? Thanks

1 · Reply

De_man Jul. 10 at 2:29 PM

$ONCY Today's pr is interesting as we just had a kol discussion in April. Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers Apr 10, 2025, 07:00 ET SAN DIEGO and CALGARY, AB, April 10, 2025 /PRNewswire/ — Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, was discussed by field-leading key opinion leaders (KOLs) during a recent event hosted by H.C. Wainwright. What is different is that this time it seems to be more of a panel with a q&a so will be interesting to see who attends or if the questions will be more or less by the moderator of the webinar. I think some might have been expecting more than this for a pr and possibly why the price is down a bit and the company knows that they need 10 consecutive days to stay on the nasdaq unless granted an extension.

2 · Reply

De_man Jul. 10 at 2:21 PM

$ONCY All you had to do was read the past news releases to know that Matt Coffey had stepped down as CEO and director Feb 07, 2025, 21:24 ET Search for Chief Executive Officer to commence immediately SAN DIEGO and CALGARY, AB, Feb. 7, 2025 /PRNewswire/ — Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that Matt Coffey, Ph.D., President and Chief Executive Officer, will not return following a medical leave of absence and ongoing health concerns. After much thought and consideration, Dr. Coffey reached a decision that in the best interest of his family and Oncolytics Biotech Inc., he would officially step down as CEO and Director of the company.

0 · Reply

Oncolytics Biotech® to Host Key Opinion Leader Discussion Focusing on Pancreatic and Gastrointestinal Cancers

Jul 8, 2025, 8:30 AM EDT - 5 days ago

Oncolytics Biotech® Highlights Transformative Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-Enabling Studies

Jun 30, 2025, 7:00 AM EDT - 13 days ago

Oncolytics Biotech® Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy

Jun 11, 2025, 7:00 AM EDT - 4 weeks ago

Oncolytics Biotech® Names New CEO to Accelerate Momentum in Immunotherapy Programs

May 23, 2025, 7:00 AM EDT - 7 weeks ago

Oncolytics Biotech® to Present New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities

May 14, 2025, 7:21 PM EDT - 2 months ago

Oncolytics Biotech Inc. (ONCY) Q1 2025 Earnings Call Transcript

May 14, 2025, 4:01 PM EDT - 2 months ago

Oncolytics Biotech® Reports First Quarter Financial Results and Highlights Clinical Momentum

May 6, 2025, 7:00 AM EDT - 2 months ago

Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights

Apr 24, 2025, 7:00 AM EDT - 2 months ago

Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of Action

Apr 10, 2025, 6:09 PM EDT - 3 months ago

Oncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital

Apr 10, 2025, 7:00 AM EDT - 3 months ago

Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers

Mar 7, 2025, 11:11 AM EST - 4 months ago

Oncolytics Biotech Inc. (ONCY) Q4 2024 Earnings Call Transcript

Mar 7, 2025, 7:00 AM EST - 4 months ago

Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024

Feb 25, 2025, 7:00 AM EST - 4 months ago

Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights

Feb 19, 2025, 7:00 AM EST - 5 months ago

Oncolytics Biotech® Advances Key Pancreatic and Anal Cancer Trials, Strengthening Pipeline in 2025

Feb 18, 2025, 7:00 AM EST - 5 months ago

Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer

Feb 14, 2025, 5:15 PM EST - 5 months ago

Oncolytics Biotech® Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

Feb 7, 2025, 9:24 PM EST - 5 months ago

Oncolytics Biotech® Announces Matt Coffey, Ph.D. Will Not Return to CEO Role Following Medical Leave of Absence

Jan 22, 2025, 7:00 AM EST - 6 months ago

Oncolytics Biotech® to Present Compelling New Efficacy and Safety Data in Anal and Pancreatic Cancers at 2025 ASCO GI Symposium

Jan 15, 2025, 7:02 AM EST - 6 months ago

Regulatory Approval Clears Path for Oncolytics Biotech® to Advance Promising Pancreatic Cancer Treatment, Following a Review of Safety Data

Dec 23, 2024, 7:00 AM EST - 7 months ago

Oncolytics Biotech® Highlights 2024 Achievements and Prepares for an Influential 2025 with Promising Breast and GI Cancer Data

Dec 18, 2024, 7:00 AM EST - 7 months ago

Oncolytics Biotech® to Present Promising Pelareorep Data in Pancreatic and Anal Cancers at ASCO GI Symposium

Dec 3, 2024, 7:00 AM EST - 7 months ago

Oncolytics Biotech® Reports Completion of Initial Safety Phase Enrollment for GOBLET Trial's New Pancreatic Cancer Cohort

Nov 13, 2024, 9:01 PM EST - 8 months ago

Oncolytics Biotech Inc. (ONCY) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 7:00 AM EST - 8 months ago

Oncolytics Biotech® Reports Third Quarter 2024 Financial Results and Operational Highlights

Nov 11, 2024, 7:00 AM EST - 8 months ago

Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights

Oct 4, 2024, 7:00 AM EDT - 10 months ago

Oncolytics Biotech® Announces Key Progress and Upcoming Studies for Breast and Pancreatic Cancer Treatments, Prepares for FDA Accelerated Approval Path

Sep 19, 2024, 7:00 AM EDT - 10 months ago

Oncolytics Biotech® Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study

Sep 6, 2024, 8:00 AM EDT - 11 months ago

Oncolytics Biotech® to Participate in Fireside Chats at Two Investment Conferences in September

Aug 2, 2024, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® to Participate in a Fireside Chat at Canaccord Genuity's 44th Annual Growth Conference

Aug 1, 2024, 7:55 PM EDT - 1 year ago

Oncolytics Biotech Inc. (ONCY) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 4:01 PM EDT - 1 year ago

Oncolytics Biotech® Reports Second Quarter 2024 Financial Results and Operational Highlights

Jul 24, 2024, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational Highlights

Jun 27, 2024, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer Program

Jun 24, 2024, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® Announces President and Chief Executive Officer Dr. Matt Coffey to Take Medical Leave of Absence

Jun 20, 2024, 7:26 AM EDT - 1 year ago

Oncolytics Biotech® Doses First Patient in Study of Pelareorep/FOLFIRINOX Combination Therapy in Pancreatic Cancer

May 24, 2024, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® ASCO Abstracts Highlight Pelareorep's Potential in Pancreatic Cancer and Immunotherapeutic Mechanism of Action

May 16, 2024, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders

May 15, 2024, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial

May 9, 2024, 8:48 PM EDT - 1 year ago

Oncolytics Biotech, Inc. (ONCY) Q1 2024 Earnings Call Transcript

May 9, 2024, 4:01 PM EDT - 1 year ago

Oncolytics Biotech® Reports First Quarter 2024 Financial Results and Operational Highlights

May 9, 2024, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer

May 8, 2024, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® to Participate in a Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference

Apr 25, 2024, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting

Apr 11, 2024, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA

Apr 2, 2024, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® to Participate in a Panel Presentation at Canaccord Genuity's Horizons in Oncology Virtual Conference

Mar 9, 2024, 1:09 AM EST - 1 year ago

Oncolytics Biotech, Inc. (ONCY) Q4 2023 Earnings Call Transcript

Mar 7, 2024, 4:01 PM EST - 1 year ago

Oncolytics Biotech® Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

Mar 6, 2024, 8:00 AM EST - 1 year ago

Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning

BLRX CADL IMRX

Mar 5, 2024, 7:00 AM EST - 1 year ago

Oncolytics Biotech® Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN

ChartGeek Jul. 12 at 12:49 AM

$ONCY on watchlist

0 · Reply

cbachand Jul. 11 at 5:39 PM

0 · Reply

JoeZa Jul. 11 at 2:16 PM

$ALT picked up a position $ONCY

1 · Reply

CaseyLe Jul. 11 at 1:13 PM

$ONCY 73 days left

1 · Reply

Arrankar2099 Jul. 11 at 6:33 AM

$ONCY

1 · Reply

De_man Jul. 11 at 12:16 AM

1 · Reply

sam92 Jul. 10 at 4:50 PM

$ONCY Latest Report 07/09/2025 LSEG maintains a current price target of $3.43 for ONCY

0 · Reply

Lovelife68 Jul. 10 at 3:20 PM

$ONCY hi how much cash does oncy have? Thanks

1 · Reply

De_man Jul. 10 at 2:29 PM

2 · Reply

De_man Jul. 10 at 2:21 PM

0 · Reply

Johnm_ Jul. 10 at 12:50 PM

$ONCY Breaking News : Oncolytics Biotech® to Host Key Opinion Leader Discussion Focusing on Pancreatic and Gastrointestinal Cancers https://finance.yahoo.com/news/oncolytics-biotech-host-key-opinion-123000037.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr

0 · Reply

CaseyLe Jul. 10 at 12:37 PM

$ONCY https://oncolyticsbiotech.com/press_releases/oncolytics-biotech-to-host-key-opinion-leader-discussion-focusing-on-pancreatic-and-gastrointestinal-cancers/

0 · Reply

Qport Jul. 10 at 12:24 PM

$ONCY latest 6K, looks like Matt C. No longer on directors list for Aug 6

1 · Reply

sam92 Jul. 10 at 10:00 AM

$ONCY Hitting the bullish scanner

0 · Reply

sam92 Jul. 9 at 7:04 PM

$ONCY Latest Report 07/09/2025 LSEG maintains a current price target of $3.43 for ONCY

0 · Reply

exwallstcfo Jul. 9 at 4:25 PM

$XBI long term buy signal getting very close 89.07 the 200 dma I said earlier in year that biotechs especially small nano caps would start a bull run in 2nd half of year .. WATCH OUT !!!! for $ONCY and $TOVX

1 · Reply

GoPatzGo123 Jul. 9 at 4:22 PM

$ONCY hey gopatzgo here i lost all my contacts new phone please add me and i will add back

1 · Reply

JoeZa Jul. 9 at 3:32 PM

$ONCY well if schwab would settle my cash i would buy this now. I guess ill wait until tomorrow.

0 · Reply

Apeezy79 Jul. 9 at 2:31 PM

$ONCY more, more, more

0 · Reply

Howie_FelderScratch Jul. 9 at 12:47 PM

$ONCY Load 4/1/04 or at least 12/1/10 fundamentals please, hedgie mofo

0 · Reply

m00nsh0t Jul. 9 at 11:50 AM

$ONCY anyone else having a problem with stock house website?

0 · Reply

LegendaryCharts Jul. 9 at 9:26 AM

What is happening to APLM right now?! Seems like volume could be shifting in to APLM! This could be the next multi - day runner! APLM moves like a true nano nano floater! Show me some 50K buying candles and this could HALT UP and spike to 15+$ Some will buy now some will chase later! $RIVN $NIO $ONCY $DGLY ,x

0 · Reply

Market Cap	111.26M
Revenue (ttm)	0.00
Net Income (ttm)	-23.14M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,059,500
Avg Vol	1,160,612
Day's Range	N/A - N/A
Shares Out	94.28M
Stochastic %K	78%
Beta	1.07
Analysts	Strong Sell
Price Target	$3.53